Regarding the efficacy of TNF antagonists for the AS-related IBD manifestation from the literature, the receptor fusion protein ETA appears to have much inferior protection effects as compared with mAbs (Table 2). The gene discussed is TNF; the disease is inflammatory bowel disease.